



MERGER ANNOUNCEMENT - M/18/070

Competition and Consumer Protection Commission clears proposed acquisition by Cooperatief H2 Equity Partners Fund V U.A. and Primacy Healthcare 21 Holding Company Unlimited Company of joint control of Primacy Healthcare 21 Limited, and the proposed acquisition of sole control by Primacy Healthcare 21 Limited of Healthcare Acquisition Limited.

26 September 2018

On 26 September 2018, the Competition and Consumer Protection Commission cleared the proposed transaction whereby, (1) Cooperatief H2 Equity Partners Fund V U.A. and Primacy Healthcare 21 Holding Company Unlimited Company would acquire joint control of Primacy Healthcare 21 Limited; and (2) Primacy Healthcare 21 Limited would acquire sole control of the Aquilant Target Group via its acquisition of Healthcare Acquisition Limited. The proposed transaction was notified under the Competition Act 2002, as amended, on 23 August 2018.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Additional Information

Cooperatief H2 Equity Partners Fund V U.A. is a private equity pound sterling denominated fund, focused on making investments in the UK and Ireland, as well as in the Benelux region. Cooperatief H2 Equity Partners Fund V U.A. operates out of its offices in London and Amsterdam.

Primacy Healthcare 21 Limited is a privately owned healthcare company, incorporated in Ireland with operations in the UK, Germany, Austria and Ireland. Primacy Healthcare 21 limited is a provider of sales, marketing, customer service, engineering service and logistics for a variety of market leading global medtech manufacturers.

Primacy Healthcare 21 Holding Company Unlimited Company is an Irish incorporated company and the holding company of Primacy Healthcare 21 Limited.

Aquilant Target Group comprises Aquilant Endoscopy Limited, Aquilant Limited, Aquilant Pharmaceuticals Limited, Aquilant Analytical Sciences Limited, Aquilant Medical (ROI) Limited, Aquilant Scientific (ROI) Limited, Aquilant Northern Ireland Limited and Pyramed Limited and each of their subsidiaries. Aquilant Target Group is a provider of specialist healthcare and scientific products and services, providing outsourced sales, marketing, distribution and engineering for the medical and scientific sectors. It has operations in the UK and Ireland.